sarscov2in7

SARS-CoV-2-IN-7 demonstrates potent inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells with an IC50 value of 844 nM.

SARS-CoV-2-IN-72 (compound 12) is a potent allosteric inhibitor of the SARS-CoV-2 papain-like protease domain, capable of inducing degradation of NSP3.

SARS-CoV-2-IN-71 (compound 8h) is an effective inhibitor of SARS-CoV-2, demonstrating antiviral activity by targeting multiple stages of coronavirus replication. It exhibits its effects by simultaneously acting on 3CLpro and TMPRSS2.

SARS-CoV-2-IN-79 (Compound 5) is an inhibitor of SARS-CoV-2 with IC50 and CC50 values of 55 μg/mL and 311.6 μg/mL, respectively. It exhibits the highest antiviral activity against (hCoV-19/Egypt/NRC-03/2020). SARS-CoV-2-IN-79 is applicable for COVID-19 research.

SARS-CoV-2-IN-73 (compound 4) is an inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).

SARS-CoV-2-IN-74 (compound 30) is an epoxide inhibitor that suppresses the replication of SARS-CoV-2 in cells, with an EC68 value of 5 μM. It is applicable in coronavirus research.

SARS-CoV-2-IN-77 (compound 11e) is an inhibitor of cathepsin L and cathepsin S, with Ki values of 111 nM and 103 nM, respectively. It effectively inhibits SARS-CoV-2 in Calu-3 cells with an EC50 value of 38.4 nM and does not exhibit cytotoxicity.

SARS-CoV-2-IN-75 (compound 13), a chloroacetamide-based inhibitor, effectively suppresses cellular replication of SARS-CoV-2. It achieves a half-log reduction in viral titer (EC 68) at a concentration of 3 μM [1].

SARS-CoV-2-IN-76 (compound 1) operates as an inhibitor of both nsp14-viral cap N7 methyltransferase and PLpro in severe acute respiratory syndrome coronavirus (SARS-CoV-2) [1].

SARS-CoV-2-IN-78 (compound 3) functions as an inhibitor of nsp14 in SARS-CoV-2 and exhibits antiviral properties through its activity as an N7 methyltransferase [1].